Literature DB >> 12459378

DMXAA: an antivascular agent with multiple host responses.

Bruce C Baguley1, Lai Ming Ching.   

Abstract

PURPOSE: To measure host responses to the antivascular agent DMXAA (5,6-dimethylxanthenone-4-acetic acid) and to compare them with those of other antivascular agents.
METHODS: Induction of tumor necrosis was measured in s.c. murine Colon 38 carcinomas growing in normal or tumor necrosis factor (TNF) receptor-1 knockout mice. Plasma and tumor tissue TNF concentrations were measured by ELISA. Plasma concentrations of 5-hydroxyindoleacetic acid (as a measure of serotonin release) and nitrite (as a measure of nitric oxide release) were measured by high-performance liquid chromatography.
RESULTS: Administration of DMXAA to tumor-bearing mice increased plasma and tumor tissue-associated TNF, in addition to increasing plasma nitric oxide, distinguishing its action from that of mitotic poisons that had an antivascular action. Results from TNF receptor-1 knockout mice showed that TNF played an important role in both its antitumor action and its host toxicity. Release of serotonin occurred in response to mitotic poisons, as well as to DMXAA. CONCLUCIONS: The antivascular action of DMXAA involves in situ production in tumor tissue of a cascade of vasoactive events, including a direct effect on vascular endothelial cells and indirect vascular effects involving TNF, other cytokines, serotonin, and nitric oxide. Now that Phase I clinical trials of DMXAA are completed, the optimization of this cascade in cancer patients is a major challenge. Plasma 5-hydroxyindoleacetic acid concentrations may provide a useful surrogate marker for the antivascular effects of DMXAA and other antivascular agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12459378     DOI: 10.1016/s0360-3016(02)03920-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

Review 1.  Vascular targeting agents.

Authors:  Mary Jo Pilat; Julie McCormick; Patricia Mucci LoRusso
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 2.  Translating nucleic acid-sensing pathways into therapies.

Authors:  Tobias Junt; Winfried Barchet
Journal:  Nat Rev Immunol       Date:  2015-08-21       Impact factor: 53.106

Review 3.  STING pathway agonism as a cancer therapeutic.

Authors:  Blake A Flood; Emily F Higgs; Shuyin Li; Jason J Luke; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

4.  Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome.

Authors:  Mukund Seshadri; Joseph A Spernyak; Patricia G Maiery; Richard T Cheney; Richard Mazurchuk; David A Bellnier
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

5.  Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.

Authors:  Mukund Seshadri; David A Bellnier; Richard T Cheney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-15       Impact factor: 7.038

6.  Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells.

Authors:  Chih-Hang Anthony Tang; Joseph A Zundell; Sujeewa Ranatunga; Cindy Lin; Yulia Nefedova; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  Cancer Res       Date:  2016-03-07       Impact factor: 12.701

7.  Vascular priming enhances chemotherapeutic efficacy against head and neck cancer.

Authors:  Margaret Folaron; James Kalmuk; Jaimee Lockwood; Costakis Frangou; Jordan Vokes; Steven G Turowski; Mihai Merzianu; Nestor R Rigual; Maureen Sullivan-Nasca; Moni A Kuriakose; Wesley L Hicks; Anurag K Singh; Mukund Seshadri
Journal:  Oral Oncol       Date:  2013-07-23       Impact factor: 5.337

8.  Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA.

Authors:  Pu Gao; Manuel Ascano; Thomas Zillinger; Weiyi Wang; Peihong Dai; Artem A Serganov; Barbara L Gaffney; Stewart Shuman; Roger A Jones; Liang Deng; Gunther Hartmann; Winfried Barchet; Thomas Tuschl; Dinshaw J Patel
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

Review 9.  Delicate regulation of the cGAS-MITA-mediated innate immune response.

Authors:  Wei-Wei Luo; Hong-Bing Shu
Journal:  Cell Mol Immunol       Date:  2018-02-19       Impact factor: 11.530

10.  The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo.

Authors:  Mukund Seshadri; David A Bellnier
Journal:  Photochem Photobiol       Date:  2008-07-17       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.